Showing 6381-6390 of 7326 results for "".
- Protea Expands Clinical Study for New Melanoma Testhttps://practicaldermatology.com/news/protea-expands-clinical-study-for-new-melanoma-test/2458083/Protea Biosciences Group, Inc. is expanding its clinical research study for their new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples, the company reports. The propr
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<
- Revision Skincare Launches Nectifirm Advancedhttps://practicaldermatology.com/news/revision-skincare-launches-nectifirm-advanced/2458090/Revision Skincare® is expanding the Nectifirm® collection with Nectifirm® ADVANCED. Nectifirm® ADVANCED harnesses the power of the Microbiome for maintaining skin
- Researchers Close in on Cause of Inflammation in Rosaceahttps://practicaldermatology.com/news/researchers-close-in-on-cause-of-inflammation-in-rosacea/2458091/Once developed, therapies that block TRPV4 may help treat or prevent inflammation in patients with rosacea, according to new research funded by the National Rosacea Society (NRS). In earlier research, the team l
- Review Study Suggests Vitamin B3 May Prevent Melanomahttps://practicaldermatology.com/news/review-study-suggests-vitamin-b3-may-prevent-melanoma/2458093/Nicotinamide (Vitamin B3) may help stave off melanoma in high-risk individuals, a new review study suggests. “Nicotinamide has been shown in a clinical trial—called ONTRAC—to reduce the incidence of non-melanoma skin cancer in high-risk individuals and it would be worthw
- Bonti's Novel Gateway Neuromodulator Performs Well in Phase 2A Studyhttps://practicaldermatology.com/news/bontis-novel-serotype-e-botulinum-toxin-performs-well-in-phase-2a-study/2458094/Bonti’s lead product candidate, EB- 001, passed muster in a Phase 2A study for the treatment of glabellar lines. EB-001 is a novel serotype E botulinum neurotoxin with a unique efficacy profile, characterized by fast onset of action (about 24 hours
- Research on Nitric Oxide-Releasing Nanoparticles Reveals Promising Skin Infection Treatmenthttps://practicaldermatology.com/news/research-on-nitric-oxide-releasing-nanoparticles-reveals-promising-skin-infection-treatment/2458095/George Washington University (GW) researchers have found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophyt
- Environmental Groups Sue FDA to Take Formaldehyde Out of Salonshttps://practicaldermatology.com/news/environmental-groups-sue-fda-to-take-formaldehyde-out-of-salons/2458096/The Environmental Working Group (EWG) and Women’s Voices for the Earth (WVE) are suing the Food and Drug Administration (FDA) because of the group’s failure to act on dangerous hair straighteners that contain unsafe levels of formaldehyde and pose a significant health hazard to consum
- Serica: New Formulations Target Scars, Stretch Marks with Rain-forest Sourced Ingredientshttps://practicaldermatology.com/news/serica-new-formulations-target-scars-stretch-marks-with-rain-forest-sourced-ingredients/2458099/Serica Moisturizing Scar Formula and Serica Moisturizing Stretch Mark Formula from Cynova Laboratories, formulated with a special blend of ingredients, including Amazonian Pracaxi oil and a patented network of semipermeable silicones, are intended to help to
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz